High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma

Akhtar, Saad; Weshi, Amr El; Rahal, M.; Abdelsalam, Mahmoud; Husseini, H Al; Maghfoor, Irfan

doi:10.1038/bmt.2009.197

Cited by 23 publications

(33 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,4,5 Table 3 describes the BEAM and CBV regimens in detail. 7,11,[40][41][42] One retrospective comparison of BEAM versus CBV conditioning showed a 5-year PFS of 92% for BEAM and 73% for CBV, with no statistically significant difference in OS. 43 Differences between the groups …”

Section: Conditioning Regimensmentioning

confidence: 99%

“…5,7,8,30,40,41,[47][48][49] OS has varied between 43% and 95%, with adult series describing OS between 30% and 65%. 6,7,47 The duration of follow-up is important to note when reviewing the literature -while most patients relapse within 2 years of diagnosis, later relapses have been described post-HDCT and 38% of deaths in one series occurred between 4 and 12 years post-ASCT.…”

Section: Efficacy Of Hdct In Relapsed and Refractory Hlmentioning

confidence: 99%

“…One of the few publications describing exclusively adolescent outcomes cites an EFS and OS of 45% and 55%, respectively. 40 The adolescents treated in this series …”

Section: Efficacy Of Hdct In Relapsed and Refractory Hlmentioning

confidence: 99%

“…2,5,7,40,49,51 Those with chemotherapy-resistant disease prior to HDC have ,10% chance of cure. 5,47 While numerous prognostic variables have been published for children and adolescents, there is no reproducible and universally agreed upon model for their application in patients in this age group.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Relapsed Hodgkin lymphoma in adolescents: focus on current high-dose chemotherapy and autologous stem cell transplant

Guilcher¹,

Stewart²

2014

COAYA

View full text Add to dashboard Cite

Hodgkin lymphoma is one of the most common cancers of adolescence and young adulthood. Most patients are cured of their disease, with very high cure rates in early stage disease and improving rates of cure even in those who present with advanced stage disease. Upfront therapy often involves chemotherapy and radiation therapy; with improving cure rates, acute and late effects of therapy are informing newer treatment protocols to avoid toxicities. Those children and adolescents with refractory or relapsed disease have lower rates of cure and generally warrant more intensive therapy. High-dose chemotherapy and autologous stem cell transplantation is often administered in such cases. This intensive intervention can be curative, but carries additional risks in the short and long term. This review includes a discussion of both transplant and non-transplant therapy for relapsed disease, commonly employed conditioning regimens, acute and late toxicities of therapy, as well as quality of life data. In addition, newer approaches to therapy for Hodgkin lymphoma are reviewed, with a focus on how such novel therapies might relate to high-dose chemotherapeutic approaches.

show abstract

Section: Conditioning Regimensmentioning

confidence: 99%

Section: Efficacy Of Hdct In Relapsed and Refractory Hlmentioning

confidence: 99%

“…One of the few publications describing exclusively adolescent outcomes cites an EFS and OS of 45% and 55%, respectively. 40 The adolescents treated in this series …”

Section: Efficacy Of Hdct In Relapsed and Refractory Hlmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Relapsed Hodgkin lymphoma in adolescents: focus on current high-dose chemotherapy and autologous stem cell transplant

Guilcher¹,

Stewart²

2014

COAYA

View full text Add to dashboard Cite

show abstract

“…In adolescents the presence of B symptoms at the time of relapse confers an 11-year OS of 27% after HDT and ASCT (Akhtar, El Weshi et al 2010). …”

mentioning

confidence: 99%

Therapy for Relapsed and Refractory Pediatric Hodgkin Lymphoma

Fernández¹,

Alarcón²

2012

Hodgkin's Lymphoma

View full text Add to dashboard Cite

Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma

Harker‐Murray

Drachtman

Hodgson

et al. 2013

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90%. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk-stratified, response-based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors.

show abstract

High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma

Cited by 23 publications

References 32 publications

Relapsed Hodgkin lymphoma in adolescents: focus on current high-dose chemotherapy and autologous stem cell transplant

Relapsed Hodgkin lymphoma in adolescents: focus on current high-dose chemotherapy and autologous stem cell transplant

Therapy for Relapsed and Refractory Pediatric Hodgkin Lymphoma

Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma

Contact Info

Product

Resources

About